Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Net Cash Flow (2016 - 2025)

Tandem Diabetes Care's Net Cash Flow history spans 13 years, with the latest figure at -$2.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 114.33% year-over-year to -$2.6 million; the TTM value through Dec 2025 reached $19.8 million, up 117.21%, while the annual FY2025 figure was $19.8 million, 117.21% up from the prior year.
  • Net Cash Flow reached -$2.6 million in Q4 2025 per TNDM's latest filing, down from $27.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $47.7 million in Q4 2022 to a low of -$50.4 million in Q3 2023.
  • Average Net Cash Flow over 5 years is -$380750.0, with a median of $2.8 million recorded in 2023.
  • The largest YoY upside for Net Cash Flow was 1051.86% in 2025 against a maximum downside of 2680.52% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$41.3 million in 2021, then skyrocketed by 215.5% to $47.7 million in 2022, then tumbled by 144.41% to -$21.2 million in 2023, then surged by 185.11% to $18.0 million in 2024, then crashed by 114.33% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Net Cash Flow are -$2.6 million (Q4 2025), $27.2 million (Q3 2025), and $8.9 million (Q2 2025).